NeoGenomics, Inc. ("NeoGenomics" or the "Company") , a leading provider of oncology diagnostic solutions that enable precision medicine, will debut its PanTracertm Family, a comprehensive suite of ...

Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the subtypes ...

Folate receptor α (FOLR1) is highly expressed in the surface of tumoral cells in several cancer types, while it shows limited expression in normal tissues. CSPC Pharmaceutical Group Ltd. has developed ...

Notably, FRα is a protein commonly found on the surface of cancer cells, according to the National Institutes of Health, and is produced by the FOLR1 gene, serving as a useful target for therapies ...

Eligibility criteria include patients with PROC whose tumors express high levels of FRα, using the Ventana FOLR1 RxDx Assay, and who have been treated with up to three prior regimens. The primary ...

A method for treating a human patient having an FOLR1-expressing ovarian cancer or cancer of the peritoneum comprising administering to the patient an immunoconjugate which binds to FOLR1 ...

It is an antibody drug conjugate (ADC) bearing a topoisomerase 1 inhibitor payload which acts by targeting FOLR1 alpha receptor. It acts by targeting folate receptor alpha. It is administered through ...

high-grade serous ovarian cancer with tumors expressing high levels of FRα (≥ 75% of cells with ≥ 2+ staining intensity), confirmed with the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Patients ...

To determine biomarker status, patients can be tested with Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay at diagnosis or at the first sign of resistance to platinum-based chemotherapy. AbbVie ...

Credit: Jo Panuwat D / Shutterstock. Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, for the identification of ...

NEW YORK – Roche on Monday announced that its Ventana FOLR1 (FOLR1-2.1) RxDx assay has received CE marking for use as a companion diagnostic with Abbvie's Elahere (mirvetuximab soravtansine) in ...